Table 2.

ENaC functional studies in split-open collecting ducts in WT and _CDPRR-KO mice

Group	fNPo	Po	fN
WT sham	0.31 ± 0.06	0.32 ± 0.03	0.87 ± 0.12
WT sham + ANG II	1.63 ± 0.25*	0.57 ± 0.04*	3.73 ± 0.39*
WT sham + ANG II + spironolactone	0.91 ± 0.09*	0.52 ± 0.03*	1.82 ± 0.18*
CDPRR-KO sham	0.28 ± 0.05	0.30 ± 0.04	0.92 ± 0.11
CDPRR-KO + ANG II	1.11 ± 0.15*#	0.41 ± 0.03*#	2.47 ± 0.26*#
CDPRR-KO + ANG II + spironolactone	0.87 ± 0.13*	0.41 ± 0.03*	2.01 ± 0.24

Data presented as means ± SE. Summary of total ENaC activity (fNPo), functional ENaC expression (fN), and ENaC open probability (P_o) in wild-type (WT) and _CDPRR-KO mice after 2 wk of infusions with vehicle (sham; n = 6), ANG II (n = 6), and ANG II plus spironolactone 30 mg/kg body wt in drinking water (n = 6).

^*P < 0.05 vs. sham WT split-open collecting ducts (n = 40–50);

^#P < 0.05 vs. WT corresponding treatment.